Thiazolidinone-based compounds as dual-purpose therapeutics: antimicrobial efficacy, cytotoxicity and pharmacokinetic potential
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F25%3A73635354" target="_blank" >RIV/61989592:15110/25:73635354 - isvavai.cz</a>
Result on the web
<a href="https://journals.uran.ua/sr_pharm/article/view/342467" target="_blank" >https://journals.uran.ua/sr_pharm/article/view/342467</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.15587/2519-4852.2025.342467" target="_blank" >10.15587/2519-4852.2025.342467</a>
Alternative languages
Result language
angličtina
Original language name
Thiazolidinone-based compounds as dual-purpose therapeutics: antimicrobial efficacy, cytotoxicity and pharmacokinetic potential
Original language description
Infectious diseases and cancer remain leading global health challenges, with rising resistance to existing antibiotics and limited selectivity of many cytotoxic agents. Heterocyclic scaffolds, particularly thiazolidinones, offer a promising platform for the development of novel antimicrobial and anticancer compounds. The aim of the study. To evaluate the antimicrobial and cytotoxic properties of thiazolidinone-based compounds against a panel of pathogenic microorganisms and human cancer cell lines, and to identify the most promising derivatives with favorable safety, pharmacokinetic, and mechanistic profiles through molecular docking and dynamics studies. Materials and methods. A library of 5-enamine(hydrazine)-4-thiazolidinone derivatives was screened for antimi-crobial activity against Gram-positive and Gram-negative bacteria and Candida albicans, and for cytotoxic activity against six human cancer cell lines. Minimum inhibitory concentrations (MIC) were determined, and IC50 values were measured for selected compounds. Pharmacokinetic properties, including gastrointestinal absorption and li-pophilicity, were assessed in silico. To investigate potential mechanisms of antibacterial action, molecular docking was performed against MurB
Czech name
—
Czech description
—
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
10608 - Biochemistry and molecular biology
Result continuities
Project
<a href="/en/project/LX22NPO5103" target="_blank" >LX22NPO5103: National Institute of Virology and Bacteriology</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>S - Specificky vyzkum na vysokych skolach
Others
Publication year
2025
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
ScienceRise: Pharmaceutical Science
ISSN
2519-4844
e-ISSN
2519-4852
Volume of the periodical
5
Issue of the periodical within the volume
57
Country of publishing house
UA - UKRAINE
Number of pages
14
Pages from-to
88-101
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-105022489828